PRIMARY RESEARCH
LncRNA NNT-AS1 contributes to the cisplatin
resistance of cervical cancer through NNT-AS1/
miR-186/HMGB1 axis
Yanjie Liu
1*, Ruixia Guo
1, Yuhuan Qiao
1, Liping Han
1and Mingzhu Liu
2Abstract
Background: Cisplatin (DDP) is a major chemotherapeutic drug which was widely used for cervical cancer (CC) patients with advanced or recurrent although its limitation in the development of resistance. LncRNA nicotinamide nucleotide transhydrogenase-antisense RNA1 (NNT-AS1) has been reported to be involved in the DDP resistance. However, the role of NNT-AS1 in DDP resistance in CC remain unknown.
Methods: The mRNA expression of NNT-AS1, microRNA-186 (miR-186) and HMGB1 was detected by quantitative real-time polymerase chain reaction (qRT-PCR). Cell proliferation and apoptosis abilities were measured via MTT assay or flow cytometry, respectively. Western blot was used to measure the expression level of HMGB1, Bax, Bcl-2, Cleaved-caspase 3, N-cadherin, Vimentin and E-cadherin. Cell migration and invasion abilities were analyzed using Transwell assay. The interaction among NNT-AS1, miR-186 and HMGB1 was confirmed by luciferase reporter assay and RNA pull-down assay. Murine xenograft model was established using stably transfected SiHa/DDP cells.
Results: NNT-AS1 level was significantly elevated in CC tissues and cells, especially in DDP-resistant tumors and cell lines. Subsequently, loss-of function assays indicated that NNT-AS1 silence could attenuate DDP resistance by inhibit-ing proliferation, metastasis and EMT but inducinhibit-ing apoptosis in DDP-resistant CC cells. Besides that, knockdown of NNT-AS1 also antagonized DDP resistance in vivo. Bioinformatics predication revealed NNT-AS1 directly bound to miR-186 and HMGB1 was a target of miR-186. Additionally, NNT-AS1 could regulate HMGB1 expression via targeting miR-186. Furthermore, restoration experiments showed NNT-AS1 knockdown might improve DDP-sensitivity of CC cells via blocking HMGB1 expression by competitive interaction with miR-186.
Conclusion: NNT-AS1 improved chemoresistance of DDP-resistant CC cells via modulating miR-186/HMGB1 axis. Keywords: NNT-AS1, miR-186, HMGB1, Cisplatin resistance, Cervical cancer
© The Author(s) 2020. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creat iveco mmons .org/licen ses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creat iveco mmons .org/publi cdoma in/ zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background
Cervical cancer (CC) is the second most common female cancer worldwide, and is the leading cause of mortal-ity from cancer among females in developing countries [1]. Though great advances aimed at the development of therapy for preventing CC in recent decades, about
20–25% patients remain suffer from treatment failure because of distant metastasis and recurrence [2, 3]. Cispl-atin (DDP) is a widely used chemotherapeutic drug, and is often used to combination with radiotherapy for the treatment of patients with advanced or recurrent CC [4]. However, the development of resistance to DDP-based chemotherapy has become a major limiting factor for its efficacy as an anticancer drug [5].
Long non-coding RNAs (lncRNAs) are RNA tran-scripts longer than 200 nucleotides in length and are not translated into protein [6]. Nevertheless, emerging
Open Access
*Correspondence: milin5375939@163.com
evidence has revealed that lncRNAs involve in multiple biological activities, such as gene regulation, RNA trans-port and protein synthesis [7, 8]. Recently, lncRNAs were evidently discovered to modulate drug transport and ultimate resistance [9]. Many lncRNAs are reported to mediate DDP resistance in cancers. For example, lncRNA XIST promoted DDP resistance of human lung adeno-carcinoma cells via let-7i/BAG-1 axis [10]. LncRNA UCA1 promoted proliferation and DDP resistance of oral squamous cell carcinoma by suppressing miR-184 expression [11]. LncRNA CCAT1/miR-130a-3p axis increased DDP resistance in non-small-cell lung cancer cell line by targeting SOX4 [12]. In recent, LncRNA nico-tinamide nucleotide transhydrogenase-antisense RNA1 (NNT-AS1), located in the chromosome 5p12 region, has been reported to be highly expressed in drug-resistant NSCLC tissues and cells, and promote the resistance of NSCLC cells to DDP through the MAPK/Slug signal-ing pathway [13], indicating NNT-AS1 may be related to DDP-resistant. Additionally, NNT-AS1 was verified to function as a tumor promoter in CC via promoting cell proliferation and invasion [14]. However, the relationship between NNT-AS1 and DDP resistance in CC has not been reported.
MicroRNAs (miRNAs), a class of small noncoding RNAs with 22 nucleotides in size, are able to bind to the 3′-untranslated region (3′UTR) of most protein-coding transcripts to lead translational repression, mRNA decay and mRNA deadenylation [15, 16]. Recently, increasing evidence has revealed that aberrantly expressed miRNAs involve in the development of drug resistance [17, 18]. MiR-186, a member of miRNAs, has also been found that can induce sensitivity of cancer cells to DDP in several tumors, including ovarian cancer, glioblastoma and lung cancer [19–21]. All the findings indicated the regulatory role of miR-186 in DDP resistance. High mobility group box 1 (HMGB1) protein is a ubiquitous chromatin com-ponent expressed in nucleated mammalian cells. HMGB1 has been identified to be involved in transcription regula-tion of many cancer genes, including BRCA1, E-selectin, TNF-α and insulin receptor [22]. Interestingly, recent evidence demonstrated that HMGB1 was overexpressed in CC and promoted cell invasion and migration in vitro [23]. Besides that, highly expressed HMGB1 contributed to the DDP resistance in human CC cells [24]. Neverthe-less, the mechanisms underlying HMGB1 affects DDP resistance in CC remains unclear.
In the present study, we explored the expression pat-terns of NNT-AS1 in CC DDP-resistant tissues and cell lines and investigated the effects of NNT-AS1 on CC patients DDP resistance in vivo and vitro. Besides that, we also explored the potential molecular mechanisms underlying the function of NNT-AS1 on DDP resistance.
This study may contribute to provide a potential thera-peutic approach for CC treatment.
Materials and methods
Patients and specimens
The study was approved by the Ethics Committee of the First Affiliated Hospital of Zhengzhou University and written informed consents were collected from all patients and hospitals. Cervical cancer tissues and adja-cent normal tissues were collected from 58 CC patients undergoing surgical resection in the First Affiliated Hospital of Zhengzhou University and all cancer tissue samples were diagnosed as CC by pathological exami-nation. All fresh samples were snap-frozen and pre-served in liquid nitrogen until further experiments. 58 CC patients were classified into two groups depending on the sensitivity of CC patients to chemotherapy drugs: chemotherapy-sensitive group (tumor remission after 6 cycles of chemotherapy, Chemosensitive group, N = 24) and chemotherapy-resistant group (tumor stabilization or progression after 6 cycles of chemotherapy, Chem-oresistant group, N = 34). Additionally, 58 patients were divided into two groups based on the expression of NNT-AS1 to calculate the overall survival of all participants at the different periods (0, 20, 40, 60 month) after cisplatin treatment.
Cell culture and transfection
Cervical cancer cell lines HeLa and SiHa were purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA). The normal cervical epithelial cell line HaCaT was obtained from institute of Biochemistry and Cell Biology (Shanghai, China). HeLa and SiHa cells were cultured in increasing concentrations of cisplatin (Sigma, St. Louis, MO, USA) for over 6 months to estab-lish cisplatin-resistant cell lines, HeLa/DDP and SiHa/ DDP. All cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM, Gibco, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (Gibco), 100 U/mL penicillin and 100 U/mL streptomycin (SigmaAl-drich, Shanghai, China) at 37 °C with 5% CO2 in a
humid-ified atmosphere.
USA), when the HeLa/DDP and SiHa/DDP cells reached 50–60% confluence. Then cells were harvested for 48 h for the subsequent analysis.
Quantitative real‑time polymerase chain reaction (qRT‑PCR)
Total RNA was extracted from CC cells and tissues using TRIzol reagents (Invitrogen). RNA was reversely transcribed into complementary DNA (cDNA) with the help of AMV reverse transcription kits (Takara, Dalian, China). Fluorescence qRT-PCR was performed using an SYBR Premix Ex Taq II kit (Takara) according to the manufacturer’s introduction. GAPDH or U6 was as inter-nal control and the fold change was assessed using the 2−ΔΔCt method. The specific primer sequences were listed
as follows: NNT-AS1, forward, 5′-ACG TGC AGA CAA CAT CTA CCT-3′, reverse, 5′-TAC AAC ACC TTC CCG CAT -3′; miR-186, forward, 5′-CGC GGA TCC GGT TTA CAG AAC ACC CAT CAT -3′, reverse 5′-CCG CTC GAG GTG TTG ACA TTC ACA TGC TTC -3′; HMGB1, forward: 5′-GGA GAG ATG TGG AATA-3′, reverse, 5′-GGG AGT GAG TTG TGTA-3′; U6, forward 5′-CTC GCT TCG GCA GCACA-3′, reverse 5′-ACG CTT CAC GAA TTT GCG T-3′; GAPDH, forward 5′-AAC GGA TTT GGT CGT ATT GG-3′, reverse 5′-TTG ATT TTG GAG GGA TCT CG-3′.
Cell viability assay
Cell viability was determined using the 3-(4,5)-dimethyl-thiahiazo (−z-y1)-3,5-di-phenytetrazoliumromide (MTT, Beyotime, Shanghai, China) assay. Briefly, transfected DDP-resistant cells were seeded into 96-well plate with a density of 5 × 103 cells/well and incubated with
differ-ent doses of DDP. At differdiffer-ent time points, 20 μL of MTT solution was added to each well for 4 h, followed by the addition of DMSO to resolve the generated formazan. Finally, the absorbance was measured at 490 nm using a microplate reader (Bio-Rad, Hercules, CA, USA).
Cell migration and invasion assay
The migration and invasive capacities of the DDP-resist-ant cells in vitro were detected by transwell assay. Trans-fected DDP-resistant cells were seeded in the upper chamber of a 24-well plate with or without matrigel (Becton–Dickinson, Franklin Lakes, NJ, USA) in DMEM without serum and complete medium with contain-ing 10% FBS was added into the lower compartment of each well as a chemoattractant. After incubation for 24 h at 37 °C, the non-motile cells on the upper surface were removed using a dry cotton swab. Then cells attached to the bottom were fixed with methanol and stained with 0.5% crystal violet for 30 min. The cells from five randomly selected fields were counted with an inverted microscope.
Cell apoptosis analysis
Transfected DDP-resistant cells were harvested for 48 h. Then Cell apoptosis rate was analyzed using Annexin V-FITC/PI apoptosis detection kit (Solarbio, Beijing, China) according to the instructions of manu-facture. All samples were performed in triplicate.
Western blot assay
Western blot assay was conducted as previous described [12]. Immunoblot assays were performed using antibodies against HMGB1, Bax, Bcl-2, Cleaved caspase 3, N-cadherin, Vimentin, E-cadherin, as well as GAPDH.
Luciferase reporter assay
The NNT-AS1 mRNA and HMGB1 3′-UTR containing wild-type (WT) or mutant (MUT) binding sequence of miR-186 were cloned into the psiCHECK™-2 luciferase plasmid (Promega, Shanghai, China), respectively. Then, HeLa/DDP and SiHa/DDP cells were seeded in 24-well plates, followed co-transfected with NNT-AS1-WT or NNT-AS1-MUT or HMGB1-WT or HMGB1-MUT with miR-186 mimics or miR-NC respectively using Lipo-fectamine 2000 (Invitrogen). After transfection for 48 h, a dual luciferase assay kit (Promega) was used to ana-lyze the luciferase activity following the manufacturer’s instructions.
RNA pull‑down assay
For the RNA pull-down assay, 3vitro-biotinylated miRNA mimic was transfected into DDP-resistant cells. Sub-sequently, cells were lysed and cultured with streptavi-din-coupled beads to generate biotin-miRNA-lncRNA complexes. Finally. RNA was isolated and analyzed using qRT-PCR.
Murine xenograft assay
Female BALB/c mice (aged 4–6 weeks) were bought from Vital River Laboratory Animal Technology (Bei-jing, China). The experiment was permitted by the Ani-mal Research Committee of the First Affiliated Hospital of Zhengzhou University and performed in accordance with the guidelines of the National Animal Care and Ethics Institution. SiHa/DDP cells (5 × 106) transfected
samples were weighted and used for further molecular analysis.
Statistical analysis
All statistical analyses were performed with GraphPad Prism 7 (GraphPad Inc., San Diego, CA, USA). The data were expressed as the mean ± SD. The correlation among NNT-AS1, miR-186 and HMGB1 was analyzed by Pear-son’s correlation analysis. Kaplan–Meier survival curves were plotted and the difference in survival between two groups was analyzed by the log-rank test. The significant group differences were assessed by Student’s t test or one-way analysis of variance (ANOVA). P < 0.05 was con-sidered statistically significant.
Results
NNT‑AS1 is up‑regulated in DDP‑resistant CC tissues and cells lines and highly expressed NNT‑AS1 predicates poor prognosis
To explore the role of NNT-AS1 in DDP-resistant CC, the expression of NNT-AS1 was detected using qRT-PCR in DDP-sensitive and DDP-resistant CC tissues and cells. Results showed that NNT-AS1 level was significantly elevated in CC tissues and cells, especially in DDP-resist-ant tumors and cell lines (HeLa/DDP and SiHa/DDP) (Fig. 1a, c). Additionally, 58 patients who underwent DDP treatment were followed up to 60-mouth for the analysis of prognosis and the results indicated that patients with higher level of NNT-AS1 expression had a poor overall survival compared to those with lower level of NNT-AS1 expression (Fig. 1b), indicating high NNT-AS1 expres-sion predicated poor prognosis in CC patients.
Knockdown of NNT‑AS1 inhibits DDP‑resistant CC cells viability and proliferation but induces apoptosis
To further investigate the biological effects of NNT-AS1 on DDP resistance CC cells, HeLa/DDP and SiHa/DDP
cells were transfected with sh-NC or sh-NNT-AS1. Then, the transfection efficacy was verified by qRT-PCR. The result showed that NNT-AS1 expression was decreased in cells transfected with sh-NNT-AS1 (Fig. 2a). After treatment with different concentrations of cisplatin for 48 h, we found the viability of HeLa/DDP and SiHa/DDP cells was decreased with the increase of DDP concentra-tion, while NNT-AS1 deletion remarkably inhibited the proliferation ability of DDP resistant cells (Fig. 2b–e). In addition, the results of flow cytometry indicated that knockdown of NNT-AS1 significantly induced apopto-sis of reapopto-sistant cells (Fig. 2f). Meanwhile, western blot analysis results showed NNT-AS1 deletion promoted the expression of cleaved-caspase-3 and Bax but inhib-ited the level of Bcl-2 in HeLa/DDP and SiHa/DDP cells, further suggesting that knockdown of NNT-AS1 could enhance the apoptosis of resistant cells (Fig. 2g, h). In a word, knockdown of NNT-AS1 attenuated DDP resist-ance by inhibiting proliferation and inducing apoptosis in DDP-resistant CC cells.
Knockdown of NNT‑AS1 inhibits migration, invasion and EMT of DDP‑resistant CC cells
Immediately, transwell assay was performed and the results showed knockdown of NNT-AS1 could suppress migration and invasion abilities of HeLa/DDP and SiHa/ DDP cells (Fig. 3a, b). Furthermore, epithelial-mesen-chymal transition (EMT) related protein was analyzed using western blot and an inhibition of N-cadherin and Vimentin expression but an enhancement of E-cadherin expression induced by NNT-AS1 deletion was investi-gated in HeLa/DDP and SiHa/DDP cells (Fig. 3c, d) indi-cating knockdown of NNT-AS1 could inhibit resistant cells EMT in CC. In all, we illustrated that knockdown of NNT-AS1 could attenuate DDP resistance by inhibiting proliferation metastasis and EMT in DDP-resistant CC cells.
NNT‑AS1 directly bind to miR‑186 and negatively regulates its expression
The expression of miR-186 was detected and we found miR-186 was down-regulated in CC tissues and cell lines compared to the normal tissues and cells, especially decreased in DDP-resistant tumors and cell lines (Fig. 4a, b). Subsequently, a perfect negative correlation between miR-186 and NNT-AS1 expression in CC patients was identified (R =− 0.8218, P < 0.0001) (Fig. 4c). All the results indicated that miR-186 might relate to NNT-AS1 medicated DDP-resistant. To elucidate this hypothesis, bioinformatics analysis was performed and miR-186 was predicted to be a target of NNT-AS1 with putative bind-ing sites (Fig. 4d). Then luciferase reporter assay results showed miR-186 mimic transfection reduced the lucif-erase activities of the WT-NNT-AS1 reporter vector but not empty vector or MUT-NNT-AS1 reporter vector in HeLa/DDP and SiHa/DDP cells (Fig. 4e, f). In the mean-while, The RNA pull-down assays further confirmed the direct interaction between miR-186 and NNT-AS1 because a significant enrichment of NNT-AS1 was meas-ured in both HeLa/DDP and SiHa/DDP cells (Fig. 4g).
Furthermore, qRT-PCR was carried out and we found AS1 inhibited miR-186 expression, inversely, NNT-AS1 deletion promoted miR-186 expression in HeLa/ DDP and SiHa/DDP cells (Fig. 4h). Thus, NNT-AS1 was a sponge of miR-186 and negatively regulated its expression.
Knockdown of NNT‑AS1 attenuates DDP resistance in DDP‑resistant CC cells through regulating miR‑186 To explore whether miR-186 involved in the NNT-AS1 medicated DDP resistance, HeLa/DDP and SiHa/ DDP cells were transfected with sh-NC, sh- NNT-AS1, sh-NNT-AS1 +anti-miR-NC or sh-NNT-AS1 +
attenuate DDP resistance in DDP-resistant CC cells by targeting miR-186.
HMGB1 is a target of miR‑186 and NNT‑AS1 can regulate HMGB1 expression via targeting miR‑186
The mRNA expression of HMGB1 was found to be ele-vated in both CC tissues and cells line compared with the normal tissues and cells, especially in DDP-resistant CC tissues and cells lines (Fig. 6a, b). Besides, the protein of HMGB1 was also increased in DDP-resistant CC cells (Fig. 6c). In addition, correlation analysis results showed that mRNA HMGB1 expression was negatively corre-lated with miR-186 (R =− 0.7196, P < 0.0001), but posi-tively correlated with NNT-AS1 (R = 0.6983, P < 0.0001) (Fig. 6d, e). Therefore, we hypothesized HMGB1 might involve in the NNT-AS1 medicated drug-resistant via miR-186. Subsequently, bioinformatics analysis was per-formed and HMGB1 was identified to be a candidate target gene of miR-186 (Fig. 6f). Afterwards, luciferase reporter assay results showed miR-186 mimic transfec-tion reduced the luciferase activities of the HMGB1-WT reporter vector but not empty vector or HMGB1-MUT reporter vector in HeLa/DDP and SiHa/DDP cells
(Fig. 6g, h). In the meanwhile, qRT-PCR and western blot results displayed HMGB1 expression, whether mRNA or protein, was inhibited by miR-186 mimic transfection, but was accelerated by NNT-AS1 transfection in HeLa/ DDP and SiHa/DDP cells (Fig. 6i–l), indicating NNT-AS1 could regulate HMGB1 expression via modulating miR-186. Overall, NNT-AS1 could upregulate HMGB1 expression via targeting miR-186.
Knockdown of NNT‑AS1 antagonizes DDP resistance in DDP‑resistant CC cells via regulating HMGB1
migration, invasion and EMT abilities as well as the pro-motion of apoptosis abilities in HeLa/DDP and SiHa/ DDP cells (Fig. 7c–l). Thus, we demonstrated that knock-down of NNT-AS1 might antagonize cisplatin resist-ance in cisplatin-resistant CC cells by regulating HMGB1 expression. In addition, based on the above results, NNT-AS1 knockdown might improve DDP-sensitivity of CC via blocking HMGB1 expression by competitive interac-tion with miR-186.
Knockdown of NNT‑AS1 antagonizes DDP resistance in vivo
A xenograft tumor mouse model was established to identify the impact of NNT-AS1 on DDP resistance
in vivo. SiHa/DDP cells transfected with sh-NNT-AS1 or sh-NC were subcutaneously injected into BALB/c nude mice, following by the intraperitoneal injection of DDP or PBS. Then, we found NNT-AS1 knock-down significantly prevented tumor volume and weight (Fig. 7a, b). Subsequently, qRT-PCR analysis revealed that sh-NNT-AS1 transfection decreased NNT-AS1 expression in vivo, besides that, the expression of miR-186 was increased, while HMGB1 mRNA or protein expression was reduced in tumor tissues derived from sh-NNT-AS1-transfected CC cells (Fig. 8c, d). Thus, it was concluded that knockdown of NNT-AS1 might antagonize DDP resistance in vivo via regulating miR-186 and HMGB1 expression.
Discussion
Since its discovery, DDP is considered as a pivotal drug in chemotherapy for cancers [25]. Nevertheless, it has been an impediment in using DDP for cancer treatment because of the chemoresistance in cancers [9]. Unsur-prisingly, the treatment of CC is also plagued by drug resistance. Recently, numerous studies have identified the association between the dysregulation of lncRNAs and DDP resistance in cancers, including CC, and many lncRNAs has been investigated to be implicated in the DDP resistance. For instance, lncRNA UCA1 promotes DDP resistance in CC by involving in signaling path-ways modulating cell apoptosis and proliferation [26].
LncRNA GAS5, acts as a tumor suppressor, can block DDP resistance in CC via miR-21 [27]. LncRNA ZFAS1 is upregulated in CC tissues, and its high expression indicates a poor prognosis and enhances DDP chem-oresistance [2]. All the studies revealed that lncRNAs participate in the DDP resistance in CC. NNT-AS1, a newly detected lncRNA, has been identified to play important roles in tumor progression by affecting cell proliferation, metastasis, apoptosis and tumorigenesis in many cancers via targeting downstream signaling pathway, including CC [14, 28–30]. While the effects of NNT-AS1 on CC prognosis and DDP resistance remain unknown.
In the present study, we demonstrated that NNT-AS1 was highly expressed in CC tissues and cells, which was consistent with previous study. In the meanwhile, espe-cially elevated of NNT-AS1 expression in DDP-resistant tumors and cell lines was also detected, suggesting the potential regulatory role of NNT-AS1 in DDP resist-ance of CC. The resistresist-ance towards DDP is multifaceted since it implicates multiple cellular pathways. Therefore, proliferation, migration, invasion and apoptosis abilities of DDP-resistant CC cells was evaluated and we found knockdown of NNT-AS1 could attenuate DDP resistance by inhibiting proliferation, metastasis and but inducing apoptosis in DDP-resistant CC cells. Additionally, the
acquisition of EMT features has been investigated that contributes to the DDP-resistance in cancer cells includ-ing CC. EMT was revealed to play an important role in promoting chemoresistance [31, 32]. Thus, we also illus-trated the expression levels of EMT related protein in CC DDP-resistant cells and an inhibition of N-cadherin and Vimentin expression but enhancement of E-cad-herin expression induced by NNT-AS1 deletion in DDP cells, indicating NNT-AS1 stimulated EMT and induced DDP resistance in CC cells. Besides that, a murine xen-ograft model was established using stably transfected SiHa/DDP cells and the results showed that NNT-AS1 knockdown significantly prevented tumor volume and Fig. 6 HMGB1 is a target of miR-186 and NNT-AS1 can regulate HMGB1 expression via targeting miR-186. a–c The expression of HMGB1 in
weight, suggesting NNT-AS1 deletion antagonized DDP resistance in vivo, which was consistent with the results in vitro. In consideration of the above-described bio-logical behaviors of NNT-AS1, the relationship between NNT-AS1 and overall survival was evaluated and highly expressed NNT-AS1 was identified to predicate poor prognosis in CC patients.
It has been reported that lncRNA could act as compet-ing endogenous RNA (ceRNA) of miRNAs to indirectly regulate gene expression implicated in various biological processes, including cancer [33]. MiR-186 was found to be a target of NNT-AS1 using bioinformatics prediction program and then NNT-AS1 directly binding to miR-186
was verified by luciferase reporter assay and RNA pull down assay. Subsequently, miR-186 expression was analyzed and miR-186 was demonstrated to be down-regulated in CC tissues and cell lines, especially in DDP-resistant tumors and cell lines. Immediately, a perfect negative correlation between miR-186 and NNT-AS1 expression in CC patients was identified. In all, all the results indicated that miR-186 might relate to NNT-AS1-mediated DDP-resistant.
to verify whether miR-186 related to NNT-AS1-mediated DDP-resistant, rescue experiments were performed and the data showed that miR-186 mimic transfection could restore NNT-AS1 deletion induced inhibition of DDP resistance in DDP-resistant CC cells. Therefore, NNT-AS1 improved DDP resistance in DDP-resistant CC cells by targeting miR-186.
An increasing number of findings suggests that aber-rantly expressed miRNAs promote the development of drug resistance through interfering with the expression of target proteins which may be drug targets, drug transporters, or cell-cycle- and cell apoptosis-related components, causing cells with different degrees of resistant to chemotherapeutic drugs [36]. HMGB1 has been identified that may function as a DDP-resistant regulator in DDP resistance and inhibiting the cytoplasmic location of HMGB1 can reverse DDP resist-ance in human CC cells [37]. In this study, bioinformatics prediction program and luciferase reporter assay predicted and validated that HMGB1 was a target of miR-186. Moreo-ver, expression analysis showed that NNT-AS1 could regu-late HMGB1 expression via modulating miR-186 expression in vivo and vitro. Thus, we hypothesized HMGB1 might associated with NNT-AS1/miR-186 mediated DDP-resist-ant. Immediately, rescue experiments was performed and we found knockdown of NNT-AS1 could antagonize DDP resistance in DDP-resistant CC cells via regulating HMGB1. Therefore, NNT-AS1 knockdown might improve DDP-sen-sitivity of CC cells via blocking HMGB1 expression by com-petitive interaction with miR-186.
Conclusion
We illustrated that NNT-AS1 was elevated in DDP-resistant tumor tissues and cell lines in CC, and highly expressed NNT-AS1 was associated with worse progno-sis in CC patients. In addition, NNT-AS1 contributed to the DDP resistance in CC cells through NNT-AS1/miR-186/HMGB1 axis, indicating a novel therapeutic strategy to improve the efficacy of DDP in CC chemotherapy.
Abbreviations
DDP: Cisplatin; CC: Cervical cancer; NNT-AS1: Nicotinamide nucleotide tran-shydrogenase-antisense RNA1; miR-186: MicroRNA-186; qRT-PCR: Quantitative real-time polymerase chain reaction; lncRNAs: Long non-coding RNAs; 3′UTR : 3′-untranslated region; HMGB1: High mobility group box 1; EMT: Epithelial-mesenchymal transition.
Acknowledgements
Thanks for all participants involved in this study.
Authors’ contributions
YL and ML participated in the conception and design of the study. RG per-formed the analysis and interpretation of data. YQ contributed to drafting the manuscript. LH reviewed and approved the final submitted manuscript. All authors read and approved the final manuscript.
Funding None.
Availability of data and materials
The data sets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
Ethics approval and consent to participate
of the Ethics Committee of the First Affiliated Hospital of Zhengzhou Uni-versity (No. SU864315, Date: 2018/12/20, Henan, China).Animal studies were performed in compliance with the ARRIVE guidelines and the Basel Declara-tion. Experimental procedures were approved by the Institutional and Local Committee on the Care and Use of Animals of the First Affiliated Hospital of Zhengzhou University (ACU181209) on December 28, 2018. All animals received humane care according to the National Institutes of Health (USA) guidelines.
Consent for publication Not applicable.
Competing interests
The authors declare that they have no competing interests.
Author details
1 Department of Gynaecology, The First Affiliated Hospital of Zhengzhou University, No. 1, Jianshe East Road, Zhengzhou 450052, China. 2 Gynaecologic Department of Traditional Chinese Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.
Received: 28 December 2019 Accepted: 18 May 2020
References
1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.
2. Feng LL, Shen FR, Zhou JH, Chen YG. Expression of the lncRNA ZFAS1 in cervical cancer and its correlation with prognosis and chemosensitivity. Gene. 2019;696:105–12.
3. Origoni M, Prendiville W, Paraskevaidis E. Cervical cancer prevention: new frontiers of diagnostic strategies. Biomed Res Int. 2015;2015:250917. 4. Tsuda N, Watari H, Ushijima K. Chemotherapy and molecular
tar-geting therapy for recurrent cervical cancer. Chin J Cancer Res. 2016;28(2):241–53.
5. Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene. 2003;22(47):7265–79.
6. Quinn JJ, Chang HY. Unique features of long non-coding RNA biogenesis and function. Nat Rev Genet. 2016;17(1):47–62.
7. Lee C, Kikyo N. Strategies to identify long noncoding RNAs involved in gene regulation. Cell Biosci. 2012;2(1):37.
8. Kung JT, Colognori D, Lee JT. Long noncoding RNAs: past, present, and future. Genetics. 2013;193(3):651–69.
9. Abu N, Hon KW, Jeyaraman S, Jamal R. Long noncoding RNAs as biotargets in cisplatin-based drug resistance. Future Oncol. 2018;14(29):3085–95.
10. Sun J, Pan LM, Chen LB, Wang Y. LncRNA XIST promotes human lung adenocarcinoma cells to cisplatin resistance via let-7i/BAG-1 axis. Cell Cycle. 2017;16(21):2100–7.
11. Fang Z, Zhao J, Xie W, Sun Q, Wang H, Qiao B. LncRNA UCA1 promotes proliferation and cisplatin resistance of oral squamous cell carcinoma by sunppressing miR-184 expression. Cancer Med. 2017;6(12):2897–908. 12. Hu B, Zhang H, Wang Z, Zhang F, Wei H, Li L. LncRNA CCAT1/miR-130a-3p
axis increases cisplatin resistance in non-small-cell lung cancer cell line by targeting SOX4. Cancer Biol Ther. 2017;18(12):974–83.
13. Cai Y, Dong ZY, Wang JY. LncRNA NNT-AS1 is a major mediator of cisplatin chemoresistance in non-small cell lung cancer through MAPK/Slug pathway. Eur Rev Med Pharmacol Sci. 2018;22(15):4879–87. 14. Hua F, Liu S, Zhu L, Ma N, Jiang S, Yang J. Highly expressed long
non-coding RNA NNT-AS1 promotes cell proliferation and invasion through Wnt/β-catenin signaling pathway in cervical cancer. Biomed Pharmaco-ther. 2017;92(undefined):1128–34.
15. Ha M, Kim VN. Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol. 2014;15(8):509–24.
16. Croce CM, Calin GA. miRNAs, cancer, and stem cell division. Cell. 2005;122(1):6–7.
17. Dehghanzadeh R, Jadidi-Niaragh F, Gharibi T, Yousefi M. MicroRNA-induced drug resistance in gastric cancer. Biomed Pharmacother. 2015;74:191–9.
18. Liao R, Lin Y, Zhu L. Molecular pathways involved in microRNA-mediated regulation of multidrug resistance. Mol Biol Rep. 2018;45(6):2913–23. 19. Zhu X, Shen H, Yin X, Long L, Xie C, Liu Y, Hui L, Lin X, Fang Y, Cao Y, et al.
miR-186 regulation of Twist1 and ovarian cancer sensitivity to cisplatin. Oncogene. 2016;35(3):323–32.
20. Tang N, Zhang J, Du Y. Curcumin promoted the apoptosis of cisplain-resistant human lung carcinoma cells A549/DDP through down-regulat-ing miR-186*. Zhongguo Fei Ai Za Zhi. 2010;13(4):301–6.
21. Li J, Song J, Guo F. miR-186 reverses cisplatin resistance and inhibits the formation of the glioblastoma-initiating cell phenotype by degrading Yin Yang 1 in glioblastoma. Int J Mol Med. 2019;43(1):517–24.
22. Wu T, Zhang W, Yang G, Li H, Chen Q, Song R, Zhao L. HMGB1 overexpres-sion as a prognostic factor for survival in cancer: a meta-analysis and systematic review. Oncotarget. 2016;7(31):50417–27.
23. Pang X, Zhang Y, Zhang S. High-mobility group box 1 is overexpressed in cervical carcinoma and promotes cell invasion and migration in vitro. Oncol Rep. 2017;37(2):831–40.
24. Chen J, Li G. MiR-1284 enhances sensitivity of cervical cancer cells to cisplatin via downregulating HMGB1. Biomed Pharmacother. 2018;107(undefined):997–1003.
25. Shen DW, Pouliot LM, Hall MD, Gottesman MM. Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes. Pharmacol Rev. 2012;64(3):706–21.
26. Wang B, Huang Z, Gao R, Zeng Z, Yang W, Sun Y, Wei W, Wu Z, Yu L, Li Q, et al. Expression of long noncoding rna urothelial cancer associated 1 promotes cisplatin resistance in cervical cancer. Cancer Biother Radiop-harm. 2017;32(3):101–10.
27. Wen Q, Liu Y, Lyu H, Xu X, Wu Q, Liu N, Yin Q, Li J, Sheng X. Long noncod-ing RNA GAS5, which acts as a tumor suppressor via microRNA 21, regulates cisplatin resistance expression in cervical cancer. Int J Gynecol Cancer. 2017;27(6):1096–108.
28. Shen Q, Jiang Y. LncRNA NNT-AS1 promotes the proliferation, and inva-sion of lung cancer cells via regulating miR-129-5p expresinva-sion. Biomed Pharmacother. 2018;105(undefined):176–81.
29. Li Y, Lv M, Song Z, Lou Z, Wang R, Zhuang M. Long non-coding RNA NNT-AS1 affects progression of breast cancer through miR-142-3p/ZEB1 axis. Biomed Pharmacother. 2018;103(undefined):939–46.
30. Chen B, Zhao Q, Guan L, Lv H, Bie L, Huang J, Chen XB. Long non-coding RNA NNT-AS1 sponges miR-424/E2F1 to promote the tumo-rigenesis and cell cycle progression of gastric cancer. J Cell Mol Med. 2018;22(10):4751–9.
31. Xiong Y, Sun F, Dong P, Watari H, Yue J, Yu MF, Lan CY, Wang Y, Ma ZB. iASPP induces EMT and cisplatin resistance in human cervical can-cer through miR-20a-FBXL5/BTG3 signaling. J Exp Clin Cancan-cer Res. 2017;36(1):48.
32. Song J, Li Y. miR-25-3p reverses epithelial-mesenchymal transition via targeting Sema4C in cisplatin-resistance cervical cancer cells. Cancer Sci. 2017;108(1):23–31.
33. Swain AC, Mallick B. miRNA-mediated ‘tug-of-war’ model reveals ceRNA propensity of genes in cancers. Mol Oncol. 2018;12(6):855–68. 34. Liu C, Wang J, Hu Y, Xie H, Liu M, Tang H. Upregulation of kazrin F by
miR-186 suppresses apoptosis but promotes epithelial-mesenchymal transition to contribute to malignancy in human cervical cancer cells. Chin J Cancer Res. 2017;29(1):45–56.
35. Zhang JJ, Wang DD, Du CX, Wang Y. Long noncoding RNA ANRIL pro-motes cervical cancer development by acting as a sponge of miR-186. Oncol Res. 2018;26(3):345–52.
36. Sun KX, Jiao JW, Chen S, Liu BL, Zhao Y. MicroRNA-186 induces sensitivity of ovarian cancer cells to paclitaxel and cisplatin by targeting ABCB1. J Ovarian Res. 2015;8(undefined):80.
37. Xia J, Yu X, Song X, Li G, Mao X, Zhang Y. Inhibiting the cytoplasmic location of HMGB1 reverses cisplatin resistance in human cervical cancer cells. Mol Med Rep. 2017;15(1):488–94.
Publisher’s Note
